Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of acellular DTP (component) combined vaccine (adsorbed) in 2- and 3‑month-old healthy infants
CTR20222610Phase 3Active
- Sponsor
- Wuhan Institute of Biological Products
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria + tetanus + acellular pertussis vaccine in pertussis, diphtheria, Tetanus, sponsored by Wuhan Institute of Biological Products. Started Feb 2023; status: active.
02
Drugs
diphtheria + tetanus + acellular pertussis vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on CTR20222610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222610.